Karyopharm’s Selinexor sNDA is Accepted by FDA

Share on Social Media

Karyopharm FDA acceptance of selinexor and ruxolitinib combination sNDA for myelofibrosis
Image: Pixels

FDA accepts Karyopharm’s selinexor-ruxolitinib sNDA for myelofibrosis, setting a June 28, 2027, target action date.

Written By: D. Satwika, PharmD

Reviewed By: Pharmacally Editorial Team

Karyopharm Therapeutics announced on November 17, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for XPOVIO (selinexor) in combination with ruxolitinib for the treatment of patients with myelofibrosis. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2027.

The acceptance follows Karyopharm’s August 31, 2026, submission, in which the company sought accelerated approval and requested Priority Review for the combination. The latest announcement confirms that the application has advanced into formal FDA review. However, the company announcement does not separately confirm whether the Priority Review request was granted.

FDA acceptance represents an important regulatory milestone but does not indicate that the combination has been approved. The agency will evaluate the submitted clinical and safety evidence before determining whether the proposed treatment meets the requirements for marketing authorization.

Application Supported by Phase 3 SENTRY Data

The sNDA is primarily supported by results from the Phase 3 SENTRY trial (XPORT-MF-034; NCT04562389), which evaluated once-weekly selinexor 60 mg in combination with ruxolitinib against placebo plus ruxolitinib in patients with JAK inhibitor-naïve myelofibrosis.

The trial evaluated spleen volume reduction and symptom improvement as its co-primary endpoints. Its findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the Journal of Clinical Oncology. Additional findings were presented at the 2026 European Hematology Association (EHA) Congress.

The clinical results, including the efficacy findings and their limitations, were discussed in Pharmacally’s earlier coverage of the company’s sNDA submission.

Regulatory Designations and Approval Strategy

Selinexor has received FDA Orphan Drug and Fast Track designations for myelofibrosis. These designations support the development and regulatory engagement process but do not constitute marketing approval.

In its original submission announcement, Karyopharm stated that it was seeking accelerated approval based on the potential of spleen volume reduction as a surrogate endpoint reasonably likely to predict clinical benefit. The company also indicated that longer-term overall survival follow-up from SENTRY could support confirmation of clinical benefit if accelerated approval is granted.

The FDA’s assessment will determine whether the submitted evidence supports the proposed regulatory pathway and whether additional evidence or requirements are necessary.

Regulatory Outlook

If approved, selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis, according to Karyopharm. The FDA’s decision, expected by June 28, 2027, will be an important milestone in determining the regulatory future of the combination.

The application now enters a critical review period, with the final decision dependent on the FDA’s assessment of its efficacy, safety and overall benefit-risk profile.

References

Karyopharm Therapeutics. FDA acceptance of the sNDA for XPOVIO (selinexor) plus ruxolitinib. Nov 17, 2026.

Mascarenhas J, et al. Selinexor plus ruxolitinib in JAK inhibitor-naive myelofibrosis: phase 3 SENTRY trial. J Clin Oncol. 2026;44(suppl 17): LBA6500.

Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis (SENTRY), ClinicalTrials.gov ID NCT04562389

About the Writer

D. Satwika is a Pharm.D professional (Linkedin) with clinical training and an interest in medical writing, clinical research and pharmacovigilance. Her experience includes reviewing patient and medication-related data, preparing clinical case presentations and developing scientific content. She is also a published author and poster presenter, with additional training in Good Clinical Practice, scientific writing and pharmacovigilance.

She holds certifications in ICH-GCP E6(R3) from The Global Health Network, Scientific Writing in Health Research from ICMR–NIE, Pharmacovigilance Master Class from CliniWings, and Literature Search, EndNote and Publication Writing from CliniWings.


Share on Social Media
Scroll to Top